Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

31results about How to "Treating obesity" patented technology

Stomach prosthesis

InactiveUS7037343B2Treating obesityFacilitate expedite mixing breaking downDiagnosticsSurgeryPylorusSmall intestine
An implantable stomach prosthesis is provided for surgically replacing or augmenting all or part of the antrum and / or pylorus of a stomach. The prosthesis controls the passage of food from the stomach to the small intestine. The prosthesis may be configured to churn ingested material and release it from the stomach through a prosthetic pyloric valve. At least one expandable member is arranged to be expanded to control the passage of food and / or to mimic the churning action of a patient's stomach. The prosthesis includes an outer support structure, a flexible inner member forming a conduit for the movement of material, and at least one expandable member located between the outer support structure and inner member. An implantable pump system is provided for inflating and deflating the expandable member(s).
Owner:PYTHON MEDICAL

Intragastric space filler

InactiveUS20070100367A1Little and minimal effectReducing stomachSurgeryDilatorsUrologyStomach
A gastric space filler device for treating obesity in a patient by reducing the stomach volume comprising an inflatable space filler and a safety element secured to the space filler, wherein the safety element yields a noticeable signal for causing removal of the space filler.
Owner:RESHAPE MEDICAL LLC

Intragastric space filler

InactiveUS20070100368A1Treating obesityLittle and minimal effectSurgeryDilatorsObesityUrology
A gastric space filler device for treating obesity in a patient by reducing the stomach volume comprising an inflatable space filler and a safety element secured to the space filler, wherein the safety element yields a noticeable signal for causing removal of the space filler.
Owner:RESHAPE MEDICAL CORP

Anti-obesity stent

InactiveUS20070282453A1Reduces prevents mixingReduce exposureStentsWound drainsCatheterGuide tube
The anti-obesity stent includes a tubular structure having outer and inner surfaces and proximal and distal ends. The tubular structure is sized to fit within a duodenum in substantially coaxial relation therewith. The tubular structure is impervious or semi-permeable to digestive substances and chyme within the duodenum. The anti-obesity stent includes a transport structure at least a part of which is coincident with or connected to the outer surface. The transport structure extends to the distal end of the tubular structure. At least one retainer structure is connected to the tubular structure. The retainer structure secures the tubular structure within the duodenum such that the transport structure is positioned to receive digestive fluids from a papilla of Vater on an inner surface of the duodenum. The transport structure provides a conduit for the digestive fluids therein to flow to the distal end.
Owner:BOSTON SCI SCIMED INC

Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar

InactiveUS20070027493A1Reduce rise in blood insulin levelReduce volumeElectrotherapyElectricityGlucose polymers
A method and apparatus are provided for treating a subject. An electrical signal is applied to at least one stomach site of the subject. The electrical signal is configured to reduce a rise in a blood glucose level of the subject, in order to treat the subject.
Owner:TYLERTON INT INC

Gastrointestinal methods and apparatus for use in treating disorders

A method is provided for detecting a change in posture of a subject. An electrical impedance is measured between two or more sites on a stomach (20) of the subject, and an impedance signal is generated responsive thereto. The change in posture is detected by performing a posture analysis of the impedance signal. A method is also provided for treating a subject. The method includes applying an electrical signal to a site of the subject selected from the list consisting of: a colon (402) of the subject, and a distal small intestine (408) of the subject. The signal is configured to stimulate cells of the subject to increase secretion of glucagon-like-peptide-1 (GLP-1) or PYY, or to decrease secretion of ghrelin, in order to treat the subject.
Owner:TYLERTON INT INC

Apparatus for treating obesity by extracting food

The present invention is directed to an apparatus and method for treating obesity. A tube is positioned that passes through a patient's abdominal wall into the upper digestive system of the patient. The patient is allowed to carry out his / her everyday affairs including ingesting food. After the patient has ingested food, the food is extracted by pumping it out of the upper digestive system through the tube. The present invention is less invasive than current surgical procedures for reducing weight and allows patients to live a normal and active lifestyle without experiencing adverse side effects.
Owner:ASPIRE BARIATRICS

Anti-obesity dual stent

InactiveUS20070282452A1Reduces prevents mixingReduce exposureStentsWound drainsPylorusCatheter
The anti-obesity dual stent includes a tubular outer structure within which is located a coaxial tubular inner structure. The outer structure is sized to fit within a duodenum in substantially coaxial relation therewith. The outer and inner structures communicate with the pylorus and papilla of Vater to provide conduits for the chyme and digestive fluid. Alternatively, the anti-obesity dual stent may include a tubular papilla-supplied structure which has a lateral orientation relative to a tubular pylorus-supplied structure. The papilla-supplied and pylorus-supplied structures each are sized to fit longitudinally within the duodenum. The pylorus-supplied and papilla-supplied structures communicate with the pylorus and papilla of Vater to provide conduits for the chyme and digestive fluid.
Owner:BOSTON SCI SCIMED INC

Metabolic regulators and uses thereof

The present invention relates to metabolic regulators that affect metabolic function, for example metabolic regulators that affect muscle mass, muscle regeneration, muscle hypertrophy, fat mass, insulin and glucose sensitivity, angiogenesis and cardiovascular function. In particular, the present invention relates to modulating metabolic function by administering an effective amount of a pharmaceutical composition comprising an agent, where the agent activates or inhibits the activity and / or gene expression of the metabolic regulator. The metabolic regulators of the present invention are, for example MSP1 (2160028F08Rik; SEQ ID NO: 16); MSP2 (2310043I08Rik; SEQ ID NO: 17); MSP3 (NM_026754;1 110017116Rik; SEQ ID NO: 1); MSP4 (4732466D17Rik; SEQ BD NO: 18); MSP 5 (NM_024237; 1600015H20Rik; SEQ ID NO: 12); Ins16 (AF_156094; SEQ ID NO: 20). The present invention also provides methods to screen for agents that affect the metabolic regulators of the present invention.
Owner:TRUSTEES OF BOSTON UNIV

Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity

InactiveUS7157426B2PromotePrevent and cure diabetesBiocideNervous disorderBinding peptideDense Core Vesicles
Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY(PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity.
Owner:MDRNA

Anti-obesity stent

InactiveUS8002731B2Reduces prevents mixingReduce exposureWound drainsOesophagiInsertion stentCatheter
The anti-obesity stent includes a tubular structure having outer and inner surfaces and proximal and distal ends. The tubular structure is sized to fit within a duodenum in substantially coaxial relation therewith. The tubular structure is impervious or semi-permeable to digestive substances and chyme within the duodenum. The anti-obesity stent includes a transport structure at least a part of which is coincident with or connected to the outer surface. The transport structure extends to the distal end of the tubular structure. At least one retainer structure is connected to the tubular structure. The retainer structure secures the tubular structure within the duodenum such that the transport structure is positioned to receive digestive fluids from a papilla of Vater on an inner surface of the duodenum. The transport structure provides a conduit for the digestive fluids therein to flow to the distal end.
Owner:BOSTON SCI SCIMED INC

Nutritional compositions with lipid globules with a core comprising vegetable lipids and a coating comprising phospholipids or polar lipids

ActiveUS20110206743A1Fat massImproved body compositionBiocidePeptide/protein ingredientsBiotechnologyLipid formation
The present invention relates to a nutritional composition for infants and / or toddlers comprising a lipid component which has a large lipid globule size. The composition can be used to prevent obesity and / or improve body composition later in life. Said lipid component comprises 10-50 wt % vegetable lipids, and the lipid globules have a volume-weighted diameter above 1.0 m and / or a diameter of 2-12 m in an amount of at least 45 vol %.
Owner:NV NUTRICIA

Upper stomach gastric implants

ActiveUS20120095499A1Induce satietyReduce intakeSurgeryDilatorsImplanted deviceObesity
A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive devices do not autonomously change shape, but instead react within the stomach to induce satiety. The devices may provide slowed entry into the stomach, thus reducing the intake capacity. Additionally, the devices may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, to stimulate satiety-inducing nerves. Some devices combine two or more of these satiety-inducing features. Methods of implant are disclosed including compressing the devices within a delivery tube and transorally advancing the devices through the esophagus to be deployed within the stomach. Removal of the devices occurs in the reverse. The implants are formed of materials that permit the implant to be compressed into a substantially linear transoral delivery configuration and that will resist degradation over a period of at least six months within the stomach
Owner:APOLLO ENDOSURGERY INC

Bouchardatine, Bouchardatine derivative and preparation methods and applications of Bouchardatine and Bouchardatine derivative

Disclosed are applications of Bouchardatine and Bouchardatine derivative in preparation of an anti-obesity and fatty liver-relieving drug. The structural fomulas of the Bouchardatine and the Bouchardatine derivative are shown in a pattern (I), to be specific, R is -(CH<2>)<n>R<1>, R<1>is substituted phenyl, heterocyclic radical or substituted amidogen, and n is equal to 0, 1, 2 or 3. By the use of the Bouchardatine and the Bouchardatine derivative, differentiation of pre-adipocyte 3T3-L1 is restrained so as to reduce lipid accumulation in adipocyte 3T3-L1; lipid accumulation, caused by sodium oleate, in hepatoma carcinoma cells is reduced, zooblast triglyceride level is lowered, and anti-obesity and fatty liver-relieving effect is achieved.
Owner:SUN YAT SEN UNIV

Selective separation or extraction of steroidal glycosides by supercritical fluid extraction using carbon dioxide

A method for selectively separating desirable steroidal glycosides from undesirable components present in plant material of the Asclepiadaceae family containing the same. The method comprises contacting the plant material or material derived therefrom (herein: “the material”) with liquid or supercritical carbon dioxide under conditions whereby the desirable steroidal glycosides dissolve in the liquid or supercritical carbon dioxide in preference to the undesirable components, and subsequently recovering the desirable steroidal glycosides from the carbon dioxide solution.
Owner:CONOPCO INC D B A UNILEVER

Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor

The present invention provides a composition comprising a mixture of an exogenous ketone body, an exogenous NAD modulator and a methyl donor. Typically, exogenous NAD modulator is an exogenous nicotinamide adenine dinucleotide (NAD) precursor. The present invention also provides a method of using such a composition for treating various clinical conditions, including metabolic disorders and neurocognitive impairments. The compositions of the invention can also be used to improve human performance in various competitive or environmental conditions.
Owner:TECTON GRP LLC

Application of 20 (R)-ginsenoside Rg3 in preparing medicine for preventing and/or treating obesity and medicine

The invention discloses a novel application of 20 (R)-ginsenoside Rg3 in preparing a medicine for preventing and / or treating obesity. Tests prove that the 20 (R)-ginsenoside Rg3 is significant in curative effect on treating the obesity, rapid to take effect and low in toxic and side effects; and the 20 (R)-ginsenoside Rg3, as an obesity-treating medicine, which is safe, efficient, stable and simple in preparation process, is applicable to industrial production and is easy for popularization. The invention provides a novel medicine source for preventing and treating the obesity and complications thereof.
Owner:富力

Low dosage combinations of fluoxetine and reboxetine for treating obesity

The present invention provides a pharmaceutical composition comprising a selective serotonin reuptake inhibitor (SSRI) and a norepinephrine reuptake inhibitor (NRI), particularly, fluoxetine and reboxetine, for treating obesity. Surprisingly, the inventor of the present invention discovered that use of especially low doses of the active compounds, particularly, at most 6 mg / day of reboxetine and at most 20 mg / day of fluoxetine, wherein the reboxetinerfluoxetine ratio is from about 1:4 to about 1:6, induces an effective weight loss in obese patients. Advantageously, the combinations of the present invention include very low doses of the active ingredients, thereby decreasing possible drug-drug interactions and adverse drug reaction.
Owner:BARAK NIR

Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar

InactiveUS8792985B2Reduce volumeCause a sensation of satiety felt by the patientElectrotherapyArtificial respirationElectricityGlucose polymers
A method and apparatus are provided for treating a subject. An electrical signal is applied to at least one stomach site of the subject. The electrical signal is configured to reduce a rise in a blood glucose level of the subject, in order to treat the subject.
Owner:TYLERTON INT INC

Gastric Sponge System and Use Thereof

InactiveUS20130231692A1Inhibit migrationSubject perceptionSurgeryDilatorsEARLY SATIETYLower risk
The present invention provides a low-risk, unobtrusive and noninvasive method and system for treatment of obesity and eating disorders. The system includes a gastric sponge device suitable for placement in a stomach of a subject. The sponge device absorbs fluid upon implantation and expands in volume, thereby functioning as a space occupying device in the stomach to cause early satiety.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE

Ultrasound neuromodulation treatment of obesity and eating disorders

Disclosed are methods and systems for non-invasive neuromodulation using ultrasound to treat obesity and eating disorders. The neuromodulation can produce acute or long-term effects. The latter occur through Long-Term Depression (LTD) and Long-Term Potentiation (LTP) via training. Included is control of direction of the energy emission, intensity, frequency, pulse duration, pulse pattern, and phase / intensity relationships to targeting and accomplishing up regulation and / or down regulation.
Owner:MISHELEVICH DAVID J

Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-C]pyridine derivatives for the treatment of obesity

This invention relates to 1,5,6,7-tetrahydropynolo[3,2-c]pyridine derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.
Owner:BAYER PHARMA CORP

Fresh appetite-promoting and immunity-enhancing black juice bean noodles and preparation method thereof

The invention discloses fresh appetite-promoting and immunity-enhancing black juice bean noodles and a preparation method thereof; the fresh appetite-promoting and immuno-enhancement black juice bean noodles are prepared from the following components in parts by weight: 500-550 parts of high gluten flour, 300-350 parts of bean dregs, 25-30 parts of a cuttlefish juice, 30-35 parts of yellow wine, 10-12 parts of raw ginger, 13-15 parts of orange peel, 100-120 parts of pineapple peel dregs, 5-6 parts of table salt, 20-23 parts of fructus perillae oil, 3-3.5 parts of edible alkali, 13-15 parts of medicated leaven, 13-15 parts of endothelium corneum gigeriae galli, and 13-15 parts of cape jasmine flower. The fresh appetite-promoting and immuno-enhancement black juice bean noodles have the advantages of rich nutrition, delicate taste, black and shiny color and luster, delicious cooking liquor, strong mouthfeel, fresh preservation and no addition of preservatives, and are chewy and not easily broken; contained beneficial ingredients have the health-care effects of promoting appetite, enhancing immunity and the like.
Owner:YINGSHANG GUANSHI FLOUR PROD

A preparation method of Chinese wolfberry rice

InactiveCN104996921AReasonable dosageAvoid the problem of random dosageFood ingredient functionsFood preparationBrickGram
The present invention relates to a preparation method of Chinese wolfberry rice, and aims to solve the existing problems that few people can persevere in eating Chinese wolfberries for a long time, and the daily amount of Chinese wolfberry consumption is not easy for people to hold. The preparation methods: mixing 400-600 grams of rice and 10-20 grams of dried Chinese wolfberry products and putting the mixture into a vacuum mechanism to prepare rice bricks, thereby obtaining the Chinese wolfberry rice. Advantages of the Chinese wolfberry rice are: 1, Chinese wolfberries and rice are mixed through scientific formula and reasonable dosage, avoiding the current problem of an optional amount of Chinese wolfberry consumption when people eat the Chinese wolfberries, and the Chinese wolfberry rice does not make people get excessive internal heat, or causes nosebleeds and other uncomfortable situation. 2, the Chinese wolfberries and the rice are in the same package so that the Chinese wolfberries and the rice are convenient for taking, the Chinese wolfberries are not prone to being forgotten by people, and a combined consumption of the Chinese wolfberries and the rice as staple food can achieve the purpose that people can persevere in eating Chinese wolfberries for a long time. The Chinese wolfberry rice has effects in strengthening body function, promoting health recovery, improving body disease resistance, resisting pathogenic factor invasion, enhancing body adaptation capacity to a variety of harmful stimuli, and delaying aging.
Owner:杨宪朋
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products